Details:
Glassia is an Alpha1 -Proteinase Inhibitor (Human), indicated for chronic augmentation and maintenance therapy in individuals with clinically evident emphysema due to severe hereditary deficiency of Alpha1, also known as alpha1-antitrypsin (AAT) deficiency.
Lead Product(s): Human Alpha1-Proteinase Inhibitor
Therapeutic Area: Genetic Disease Product Name: Glassia
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2023
Details:
Elfabrio (pegunigalsidase alfa-iwxj) is a PEGylated enzyme replacement therapy (ERT) for the treatment of adult patients with Fabry disease. It is a recombinant human α–Galactosidase–A enzyme expressed in plant-cell culture that is designed to provide a long half-life.
Lead Product(s): Pegunigalsidase alfa-iwxj
Therapeutic Area: Genetic Disease Product Name: Elfabrio
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Chiesi Global Rare Diseases
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2023
Details:
PRX-102 (pegunigalsidase alfa), EC authorized, is a novel PEGylated, covalently crosslinked form of α-galactosidase-A developed as enzyme replacement therapy for fabry disease, was designed to increase plasma half-life and reduce immunogenicity, thereby enhancing efficacy.
Lead Product(s): Pegunigalsidase alfa
Therapeutic Area: Genetic Disease Product Name: PRX-102
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Chiesi Global Rare Diseases
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2023
Details:
The new agreement will allow Alnylam to utilize Medison's unique multi-regional platform to ensure that Alnylam's innovative RNAi therapeutics, such as ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran) are made available across additional countries in Europe.
Lead Product(s): Givosiran Sodium
Therapeutic Area: Genetic Disease Product Name: Givlaari
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Alnylam Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration March 09, 2023
Details:
Under the agreement with Albireo, Medison aims to commercialize Odevixibat in Canada and Israel, for the treatment of patients with cholestatic liver diseases. Odevixibat is approved in Europe as Bylvay® for the treatment of progressive familial intrahepatic cholestasis.
Lead Product(s): Odevixibat
Therapeutic Area: Genetic Disease Product Name: Bylvay
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Albireo Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 16, 2022
Details:
GLASSIA, is an Alpha1 -Proteinase Inhibitor (Human), indicated for chronic augmentation and maintenance therapy in individuals with clinically evident emphysema due to severe hereditary deficiency of Alpha1 -PI, also known as alpha1 -antitrypsin deficiency.
Lead Product(s): Alpha1-Proteinase Inhibitor
Therapeutic Area: Genetic Disease Product Name: Glassia
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
Details:
This agreement completes the multi-regional distribution agreements with Medison, announced in February, to distribute Myalept® (metreleptin) and Lojuxta® (lomitapide) in Israel, and Juxtapid® (lomitapide) in Canada.
Lead Product(s): Metreleptin
Therapeutic Area: Genetic Disease Product Name: Myalepta
Highest Development Status: Approved Product Type: Peptide
Partner/Sponsor/Collaborator: Amryt Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 08, 2021
Details:
Kamada Expects to Receive $25 Million in Revenues from Sales of GLASSIA® to Takeda in 2021 which is Takeda’s Minimum Commitment for 2021 Pursuant to the Existing Supply Agreement.
Lead Product(s): Alpha1-Proteinase Inhibitor (Human)
Therapeutic Area: Genetic Disease Product Name: Glassia
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Agreement October 07, 2020